跳到主要内容
Learn Motion
探索课程产品能力价格

下载 Learn Motion

用手机扫描二维码,下载 App。

App Store

扫码从 App Store 下载 Learn Motion打开商店页面

Google Play

扫码从 Google Play 下载 Learn Motion打开商店页面
登录
Learn Motion

Why AI-Designed Drugs Haven't Changed Medicine Yet

1The Promise and the Puzzle2From Molecule to Medicine: The Journey a Drug Must Survive3Where AI Actually Helps in the Pipeline4The Prediction Gap: When a Good Molecule Meets a Real Body5The Long, Expensive Road of Clinical Trials6Money, Incentives, and the Business of Drug Development7Regulation, Evidence, and Trust8What Would Have to Change
Where AI Actually Helps in the Pipeline

What AI is actually doing at the front of the pipeline

2 / 3
The example shows why the front end suits AI so well. A list of several thousand possible proteins is far too large to test one by one, but it is small enough for a computer to rank using data that already exists. The same is true of molecules: hundreds of candidate structures can be proposed and scored in the time it would take to make one in the lab. Notice what the system produces — a shortlist and a set of proposals. It has not tested anything. That distinction matters, because a ranked target or a well-scored molecule is a hypothesis, and the laboratory still has to decide whether it is worth pursuing.
0:00 / 0:00

Two different jobs, one shared logic

Target identification is a ranking problem: which protein is most plausibly involved in the disease and reachable by a drug. Molecule generation is a proposing problem: which chemical structures might act on that protein. Property prediction and screening sit alongside both, estimating whether a proposed molecule is likely to work and be safe enough to make. In every case AI narrows or generates options; the decision to test still belongs to the laboratory.

A concrete shape of the work

Suppose a research group is studying a disease and has a list of several thousand proteins that might be involved. Testing each one experimentally would take years. An AI system can rank that list using existing gene-activity and structural data and hand back a shortlist of a few dozen. Separately, given one chosen protein, a generative system can propose hundreds of chemical structures predicted to fit it. Neither output is a medicine. Both are starting points that a laboratory then has to test.

What this does not mean

A high-ranked target or a well-scored molecule is a hypothesis, not a result. The ranking reflects patterns in the data the system was given, and the data reflects what has already been studied. Whether the hypothesis holds in a living body is a separate question, and it is not answered by the model.

上一页2 / 3下一页

Learn Motion

生成课程,认真学会。

运营方:Wuhan Daoyin Technology Co., Ltd.

联系我们: [email protected]
隐私政策用户服务协议

© 2026 Learn Motion